Literature DB >> 11443543

The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers.

I Aksentijevich1, J Galon, M Soares, E Mansfield, K Hull, H H Oh, R Goldbach-Mansky, J Dean, B Athreya, A J Reginato, M Henrickson, B Pons-Estel, J J O'Shea, D L Kastner.   

Abstract

Mutations in the extracellular domain of the 55-kD tumor-necrosis factor (TNF) receptor (TNFRSF1A), a key regulator of inflammation, define a periodic-fever syndrome, TRAPS (TNF receptor-associated periodic syndrome [MIM 142680]), which is characterized by attacks of fever, sterile peritonitis, arthralgia, myalgia, skin rash, and/or conjunctivitis; some patients also develop systemic amyloidosis. Elsewhere we have described six disease-associated TNFRSF1A mutations, five of which disrupt extracellular cysteines involved in disulfide bonds; four other mutations have subsequently been reported. Among 150 additional patients with unexplained periodic fevers, we have identified four novel TNFRSF1A mutations (H22Y, C33G, S86P, and c.193-14 G-->A), one mutation (C30S) described by another group, and two substitutions (P46L and R92Q) present in approximately 1% of control chromosomes. The increased frequency of P46L and R92Q among patients with periodic fever, as well as functional studies of TNFRSF1A, argue that these are low-penetrance mutations rather than benign polymorphisms. The c.193-14 G-->A mutation creates a splice-acceptor site upstream of exon 3, resulting in a transcript encoding four additional extracellular amino acids. T50M and c.193-14 G-->A occur at CpG hotspots, and haplotype analysis is consistent with recurrent mutations at these sites. In contrast, although R92Q also arises at a CpG motif, we identified a common founder chromosome in unrelated individuals with this substitution. Genotype-phenotype studies identified, as carriers of cysteine mutations, 13 of 14 patients with TRAPS and amyloidosis and indicated a lower penetrance of TRAPS symptoms in individuals with noncysteine mutations. In two families with dominantly inherited disease and in 90 sporadic cases that presented with a compatible clinical history, we have not identified any TNFRSF1A mutation, despite comprehensive genomic sequencing of all of the exons, therefore suggesting further genetic heterogeneity of the periodic-fever syndromes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11443543      PMCID: PMC1235304          DOI: 10.1086/321976

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  32 in total

1.  Structures of the extracellular domain of the type I tumor necrosis factor receptor.

Authors:  J H Naismith; T Q Devine; T Kohno; S R Sprang
Journal:  Structure       Date:  1996-11-15       Impact factor: 5.006

2.  The new genomics: global views of biology.

Authors:  E S Lander
Journal:  Science       Date:  1996-10-25       Impact factor: 47.728

3.  The future of genetic studies of complex human diseases.

Authors:  N Risch; K Merikangas
Journal:  Science       Date:  1996-09-13       Impact factor: 47.728

4.  The Réunion paradox and the digenic model.

Authors:  J S Beckmann
Journal:  Am J Hum Genet       Date:  1996-12       Impact factor: 11.025

5.  Autosomal-dominant periodic fever with AA amyloidosis: Novel mutation in tumor necrosis factor receptor 1 gene Rapid Communication.

Authors:  M Jadoul; C Dodé; J P Cosyns; D Abramowicz; B Georges; M Delpech; Y Pirson
Journal:  Kidney Int       Date:  2001-05       Impact factor: 10.612

6.  Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium.

Authors: 
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

7.  Autosomal dominant familial Mediterranean fever-like syndrome with amyloidosis.

Authors:  M A Gertz; R M Petitt; J Perrault; R A Kyle
Journal:  Mayo Clin Proc       Date:  1987-12       Impact factor: 7.616

8.  Familial Hibernian fever.

Authors:  L M Williamson; D Hull; R Mehta; W G Reeves; B H Robinson; P J Toghill
Journal:  Q J Med       Date:  1982

9.  Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation.

Authors:  D W Banner; A D'Arcy; W Janes; R Gentz; H J Schoenfeld; C Broger; H Loetscher; W Lesslauer
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

10.  Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13 [corrected].

Authors:  P Fuchs; S Strehl; M Dworzak; A Himmler; P F Ambros
Journal:  Genomics       Date:  1992-05       Impact factor: 5.736

View more
  69 in total

1.  New take on comparative immunology: relevance to immunotherapy.

Authors:  Ena Wang; Adriana Albini; David F Stroncek; Francesco M Marincola
Journal:  Immunotherapy       Date:  2009-05       Impact factor: 4.196

2.  Clinical and genetic features of hereditary periodic fever syndromes in Hispanic patients: the Chilean experience.

Authors:  Cristian Vergara; Arturo Borzutzky; Miguel A Gutierrez; Sergio Iacobelli; Eduardo Talesnik; María E Martinez; Lilith Stange; Javier Basualdo; Viviana Maluje; Renato Jimenez; Roberto Wiener; Javier Tinoco; Elena Jarpa; Juan I Aróstegui; Jordi Yagüe; Manuel Alvarez-Lobos
Journal:  Clin Rheumatol       Date:  2012-01-28       Impact factor: 2.980

3.  Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study.

Authors:  Luca Cantarini; Orso Maria Lucherini; Antonio Brucato; Luca Barone; Davide Cumetti; Francesca Iacoponi; Donato Rigante; Giovanni Brambilla; Silvana Penco; Maria Giuseppina Brizi; Maria Cristina Patrosso; Guido Valesini; Bruno Frediani; Mauro Galeazzi; Rolando Cimaz; Giuseppe Paolazzi; Antonio Vitale; Massimo Imazio
Journal:  Clin Res Cardiol       Date:  2012-02-05       Impact factor: 5.460

Review 4.  Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation.

Authors:  Gina A Montealegre Sanchez; Adriana Almeida de Jesus; Raphaela Goldbach-Mansky
Journal:  Rheum Dis Clin North Am       Date:  2013-09-21       Impact factor: 2.670

5.  Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series.

Authors:  Luca Cantarini; Orso Maria Lucherini; Rolando Cimaz; Donato Rigante; Cosima Tatiana Baldari; Franco Laghi Pasini; Mauro Galeazzi
Journal:  Rheumatol Int       Date:  2010-05-15       Impact factor: 2.631

Review 6.  The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy.

Authors:  Luca Cantarini; Antonio Vitale; Orso Maria Lucherini; Caterina De Clemente; Francesco Caso; Luisa Costa; Giacomo Emmi; Elena Silvestri; Flora Magnotti; Maria Cristina Maggio; Eugenia Prinzi; Giuseppe Lopalco; Bruno Frediani; Rolando Cimaz; Mauro Galeazzi; Donato Rigante
Journal:  Clin Rheumatol       Date:  2014-06-24       Impact factor: 2.980

Review 7.  Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).

Authors:  Francesco La Torre; Maurizio Muratore; Antonio Vitale; Fulvio Moramarco; Laura Quarta; Luca Cantarini
Journal:  Rheumatol Int       Date:  2015-06-06       Impact factor: 2.631

8.  Etanercept therapy in patients with advanced primary amyloidosis.

Authors:  M A Hussein; J V Juturi; L Rybicki; S Lutton; B R Murphy; M A Karam
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

Review 9.  [Periodic fever syndromes].

Authors:  C Huemer; M Huemer
Journal:  Z Rheumatol       Date:  2006-11       Impact factor: 1.372

Review 10.  Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome.

Authors:  Donato Rigante; Giuseppe Lopalco; Antonio Vitale; Orso Maria Lucherini; Caterina De Clemente; Francesco Caso; Giacomo Emmi; Luisa Costa; Elena Silvestri; Laura Andreozzi; Florenzo Iannone; Mauro Galeazzi; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2014-06-17       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.